Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Neoplasm Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting No phase listed Observational

Explanted Lung Tissues With Pulmonary Fibrosis

NCT00515567
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Generative AI Plan for Care Lab Study

NCT07552311
View directory record Official record
Conditions
Primary Health Care
Interventions
Fitbit Plan for Care Lab, Baseline Model
Other
Lead sponsor
Fitbit LLC
Industry
Eligibility
18 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed No phase listed Observational

TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy

NCT04450992
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

NCT00526799
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Sorafenib, Topotecan
Drug
Lead sponsor
Daniela Matei, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398
View directory record Official record
Conditions
Migraine Disorder
Interventions
ALD403 (Eptinezumab)
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

NCT02100514
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615; RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
108
States / cities
Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vagus Nerve Stimulation and Stress Reduction Training for Migraine

NCT03592329
View directory record Official record
Conditions
Migraine
Interventions
Stress Reduction Training A, active tVNS, Stress Reduction Training B, sham tVNS
Behavioral · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional

MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment

NCT03798431
View directory record Official record
Conditions
Opioid-use Disorder, Anxiety, Depression, Stress Related Disorder
Interventions
M-ROCC
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

NCT02856802
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
Drug · Other
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03213002
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult, Brain Tumor, Brain Tumor, Primary, Brain Tumor Adult, Cancer, Brain Cancer
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 74 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

NCT03150329
View directory record Official record
Conditions
Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Recurrent Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL, Refractory Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
Other · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tubes Cancer, Peritoneal Cancer
Interventions
Secondary Cytoreductive Surgery, Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC), platinum-based systemic chemotherapy postoperatively
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02296801
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions
Letrozole, palbociclib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

NCT03845712
View directory record Official record
Conditions
Thymidine Kinase 2 Deficiency
Interventions
doxecitine and doxribtimine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Not applicable Interventional Results available

Economic and Functional Impact of Peri-Operative Bracing for Primary Total Knee Arthroplasty (TKA)

NCT03260699
View directory record Official record
Conditions
Arthropathy of Knee
Interventions
OCSI Rehabilitator brace
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 21, 2026, 5:49 PM EDT
Withdrawn Phase 2 Interventional

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

NCT02321306
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
LUM001
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 21, 2026, 5:49 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events

NCT03439267
View directory record Official record
Conditions
Cardiovascular Primary Prevention Strategy
Interventions
Coronary Artery Calcium Screening and Statin Treatment, Standard Treatment
Combination Product · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
50 Years to 80 Years
Enrollment
5,765 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Rural Engagement in Primary Care for Optimizing Weight Reduction

NCT02456636
View directory record Official record
Conditions
Obesity
Interventions
Fee-for-Service Model (FFS, In clinic individual visits), Patient Centered Medical Home (PCMH, In clinic group visits), Disease Management (DM, Phone group visits)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 75 Years
Enrollment
1,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 21, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Interventions
TORL-1-23, Pegfilgrastim (drug)
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 1 Interventional

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00030381
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
4'-iodo-4'-deoxydoxorubicin, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 5:49 PM EDT